

Atty Dkt. No.: SIER-022CON
USSN: 10/826,466

LISTING OF CLAIMS

RECEIVED
CENTRAL FAX CENTER

AUG 08 2006

No amendments to the claims are presented in this paper. The listing of the claims below is provided for convenience.

1-45. (Canceled)

46. (Previously Presented) A method of determining whether an agent inhibits GC-Box 5 repression of TERT transcription, said method comprising:

- (a) contacting said agent with an expression system comprising a GC-Box 5 repressor binding site and a coding sequence operably linked to a TERT promoter under conditions such that in the absence of said agent transcription of said coding sequence is repressed;
- (b) determining whether transcription of said coding sequence is repressed in the presence of said agent; and
- (c) identifying said agent as an agent that inhibits GC-Box 5 repression of TERT transcription if transcription of said coding sequence is not repressed in the presence of said agent.

47. (Canceled)

48. (Original) The method according to Claim 46, wherein said contacting step occurs in a cell.

49. (Original) The method according to Claim 46, wherein said agent is a small molecule.

50-52. (Canceled)

53. (Previously Presented) The method according to Claim 48, wherein said cell does

Atty Dkt. No.: SIER-022CON
USSN: 10/826,466

not express telomerase.

54. (Previously Presented) The method according to Claim 53, wherein said cell is an MRC5 cell.

55. (Previously Presented) The method according to Claim 46, wherein said coding sequence encodes a luciferase.

56. (Previously Presented) The method according to Claim 46, wherein said coding sequence encodes a secreted alkaline phosphatase (SEAP).

57. (Previously Presented) The method according to Claim 46, wherein said agent is a biomolecule.

58. (Previously Presented) The method according to Claim 57, wherein said biomolecule is selected from the group consisting of peptides, proteins, nucleic acids, oligonucleotides, saccharides, fatty acids, steroids, purines, pyrimidines, and derivatives or structural analogs thereof.

59. (Previously Presented) The method according to Claim 46, wherein said expression system is contained in a vector.

60. (Previously Presented) The method according to Claim 59, wherein said vector is a plasmid.

61. (Previously Presented) The method according to Claim 59, wherein said vector is a viral vector.